This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jan;17(1):14.

doi: 10.1038/s41581-020-00375-2.

Empagliflozin improves kidney outcomes in patients with heart failure and CKD

Ellen F Carney¹

Affiliations

PMID: 33173185
DOI: 10.1038/s41581-020-00375-2

Comment

Empagliflozin improves kidney outcomes in patients with heart failure and CKD

Ellen F Carney. Nat Rev Nephrol. 2021 Jan.

. 2021 Jan;17(1):14.

doi: 10.1038/s41581-020-00375-2.

Author

Ellen F Carney¹

Affiliation

¹ Nature Reviews Nephrology, . nrneph@nature.com.

PMID: 33173185
DOI: 10.1038/s41581-020-00375-2

No abstract available

PubMed Disclaimer

Comment on

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Zannad F, et al. Circulation. 2021 Jan 26;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. Circulation. 2021. PMID: 33095032 Free PMC article.

References

Original article

1. Zannad, F. et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Reduced trial. Circulation https://doi.org/10.1161/CIRCULATIONAHA.120.051685 (2020) - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group